Post by Alphamab Oncology

A historic breakthrough in first‑line HER2‑positive advanced breast cancer Alphamab Oncology announced that the Phase III study (KN026‑003) of HER2 bispecific antibody Anbenitamab in combination with HB1801 has successfully met its primary endpoint of PFS, with a favorable OS trend and a manageable safety profile. Key highlights: ✅ First head‑to‑head Phase III trial of a HER2 bispecific‑based combination to demonstrate superiority over the current standard of care (THP regimen) ✅ Statistically significant and clinically meaningful PFS benefit ✅ Potential to become the preferred first‑line treatment for HER2‑positive advanced breast cancer This marks the third consecutive positive Phase III result for KN026, reinforcing its leadership as a front‑runner among HER2 bispecific antibodies. We remain committed to bringing more effective, safer, and more convenient treatment options to patients.